Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX112 in Refractory Neurologic Autoimmune Disease
NCT07804004Phase 2Not yet recruiting
- Sponsor
- CRISPR Therapeutics
- Start
- Nov 2026
- Primary completion
- Dec 2029
01
Overview
A Phase 2 trial of zugocabtagene geleucel in multiple sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), Autoimmune Encephalitis (AE), stiff person syndrome (SPS), sponsored by CRISPR Therapeutics. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
zugocabtagene geleucel
03
Conditions
multiple sclerosis (MS)Neuromyelitis Optica Spectrum Disorder (NMOSD)myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)Autoimmune Encephalitis (AE)stiff person syndrome (SPS)
Beyond the preview
Go deeper on NCT07804004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07804004.